Low Hemoglobin Levels and Hypo-Responsiveness to Erythropoiesis-Stimulating Agent Associated With Poor Survival in Incident Japanese Hemodialysis Patients

Therapeutic Apheresis and Dialysis

Volumn 18, Issue 5, 2014, Pages 404-413

  Akizawa, Tadao ^a   Saito, Akira ^f   Gejyo, Fumitake ^g   Suzuki, Masashi ^h   Nishizawa, Yoshiki ⁱ   Tomino, Yasuhiko ^b   Tsubakihara, Yoshiharu ^j   Akiba, Takashi ^c   Hirakata, Hideki ^k   Watanabe, Yuzo ^l   Kawanishi, Hideki ^m   Bessho, Masami ⁿ   Udagawa, Yukio ^d   Aoki, Kotonari ^d   Uemura, Yukari ^e   Ohashi, Yasuo ^e  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f Department of Nephrology Shonan Tobu Sogou Hospital   (Japan)

^g NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^h Shinrakuen Hospital   (Japan)

ⁱ OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k FUKUOKA RED CROSS HOSPITAL   (Japan)

^l Kasugai Municipal Hospital   (Japan)

^m TSUCHIYA GENERAL HOSPITAL   (Japan)

ⁿ SAITAMA MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

Anemia; Epoetin beta; Erythropoiesis stimulating agent; Hemodialysis; Survival

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

AGED; ARTICLE; BRAIN HEMORRHAGE; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SHUNT OCCLUSION; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; ANEMIA; CLINICAL TRIAL; FOLLOW UP; JAPAN; METABOLISM; MIDDLE AGED; PROCEDURES; RENAL REPLACEMENT THERAPY;

AGED; ANEMIA; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HEMOGLOBINS; HUMANS; JAPAN; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RENAL DIALYSIS; SURVIVAL RATE;

EID: 84909946558     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12155     Document Type: Article

References (33)

1. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 1997;51:622-630.
2. Silverberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant 2003;18(Suppl 2):ii7-ii12.
3. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005;16:529-538.
4. Gerson A, Hwang W, Fiorenza J etal. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 2004;44:1017-1023.
5. Perlman RL, Finkelstein FO, Liu L etal. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 2005;45:658-666.
6. Locatelli F, Aljama P, Bárány P etal. European Best Practice Guidelines Working Group. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-ii47.
7. Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int 2009;75:15-24.
8. Tsubakihara Y, Nishi S, Akiba T etal. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010;14:240-275.
9. Chugai Pharmaceutical. EPOGIN Package Insert. Tokyo, Japan: Chugai Pharmaceutical, updated in June, 2010.
10. Hirasawa Y, Suzuki M, Itami N etal. Maintenance hematocrit levels and mortality in hemodialysis patients with renal anemia receiving recombinant human erythropoietin (rHuEPO) treatment (rHuEPO survey). J Jpn Soc Dial Ther 2003;36:1265-1272.
11. Nakai S, Iseki K, Itami N etal. Overview of regular dialysis treatment in Japan (as of 31 December 2010). Ther Apher Dial 2012;16:483-521.
12. Fukuma S, Yamaguchi T, Hashimoto S etal. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis 2012;59:108-116.
13. Pisoni RL, Bragg-Gresham JL, Young EW etal. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:94-111.
14. Regidor DL, Kopple JD, Kovesdy CP etal. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-1191.
15. Bradbury BD, Wang O, Critchlow CW etal. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 2008;51:62-70.
16. Kilpatrick RD, Critchlow CW, Fishbane S etal. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1077-1083.
17. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008;3:133-138.
18. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007;18:3164-3170.
19. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-1210.
20. Eckardt KU, Kim J, Kronenberg F etal. Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol 2010;21:1765-1775.
21. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337-1343.
22. Capelli JP, Kushner H. Correlates affecting survival in chronic hemodialysis patients: the combined impact of albumin and high hemoglobin levels on improving outcomes, local and national results. Hemodial Int 2008;12:450-462.
23. Locatelli F, Andrulli S, Memoli B etal. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 2006;21:991-998.
24. Stenvinkel P, Bárány P. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. Nephrol Dial Transplant 2002;17(Suppl 5):32-37.
25. Bárány P, Divino Filho JC, Bergström J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997;29:565-568.
26. KDIGO. Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int (Suppl) 2012;2:283-287.
27. Besarab A, Bolton WK, Browne JK etal. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590.
28. Singh AK, Szczech L, Tang KL etal. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.
29. Drüeke TB, Locatelli F, Clyne N etal. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084.
30. Pfeffer MA, Burdmann EA, Chen CY etal. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.
31. Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001;37:348-355.
32. Hampl H, Hennig L, Rosenberger C, Gogoll L, Riedel E, Scherhag A. Proven strategies to reduce cardiovascular mortality in hemodialysis patients. Blood Purif 2006;24:100-106.
33. Arbor Research Collaborative for Health. Annual Report of the Dialysis Outcomes and Practice Patterns Study: Hemodialysis Data 1999-2008. Ann Arbor, MI: Arbor Research Collaborative for Health, 2010.